GSK plc
XETRA:GS71

Watchlist Manager
GSK plc Logo
GSK plc
XETRA:GS71
Watchlist
Price: 20.34 EUR -2.45% Market Closed
Market Cap: 83B EUR

GSK plc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

GSK plc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
GSK plc
XETRA:GS71
Depreciation & Amortization
-£80m
CAGR 3-Years
7%
CAGR 5-Years
-4%
CAGR 10-Years
-6%
GlaxoSmithKline PLC
LSE:GSK
Depreciation & Amortization
-£80m
CAGR 3-Years
7%
CAGR 5-Years
-4%
CAGR 10-Years
-6%
AstraZeneca PLC
LSE:AZN
Depreciation & Amortization
-$4.1B
CAGR 3-Years
1%
CAGR 5-Years
-15%
CAGR 10-Years
-17%
Verona Pharma PLC
NASDAQ:VRNA
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Depreciation & Amortization
-$3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Depreciation & Amortization
-$91m
CAGR 3-Years
-2%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
No Stocks Found

GSK plc
Glance View

Market Cap
81.9B EUR
Industry
Pharmaceuticals

In the heart of the pharmaceutical landscape, GSK plc stands as a venerable institution that intertwines scientific discovery with patient well-being. Originally founded as GlaxoSmithKline, the company has navigated the evolving demands of healthcare with a deft blend of innovation and strategic acumen. As a major player in the global healthcare sector, GSK operates within three principal segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Each division dances to the beat of discovery and development, bringing forward medicines and vaccines that address acute and chronic health challenges ranging from respiratory illnesses to immunological disorders. This operational design not only aligns with the urgent medical needs of populations worldwide but also creates diverse revenue streams that fortify the company’s financial foundation. Delving deeper, GSK generates its income through a meticulously structured business approach. In Pharmaceuticals, it harnesses cutting-edge research and development to create novel therapies, with a strong emphasis on therapeutic areas such as HIV and oncology. The Vaccines division spearheads innovations by focusing on prophylactic solutions, producing vaccines that combat diseases like influenza and shingles, thereby playing a pivotal role in global public health initiatives. Meanwhile, the Consumer Healthcare unit offers a portfolio of brands that have become household staples, catering to wellness and everyday health needs. This multifaceted business model ensures that GSK remains resilient amidst the fluctuations of industry trends and regulatory landscapes, continually maintaining its relevance within the global healthcare sphere by advancing medicines and nurturing health through a blend of science and strategy.

GS71 Intrinsic Value
22.23 EUR
Undervaluation 9%
Intrinsic Value
Price

See Also

What is GSK plc's Depreciation & Amortization?
Depreciation & Amortization
-80m GBP

Based on the financial report for Sep 30, 2025, GSK plc's Depreciation & Amortization amounts to -80m GBP.

What is GSK plc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-6%

Over the last year, the Depreciation & Amortization growth was -48%. The average annual Depreciation & Amortization growth rates for GSK plc have been 7% over the past three years , -4% over the past five years , and -6% over the past ten years .

Back to Top